Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement

New York, New York (PRWEB) November 17, 2013

As Risperdal lawsuits ( ) over allegations that use of drug may cause gynecomastia, or male breast growth, continue to move forward, Bernstein Liebhard LLP notes that the U.S. Department of Justice has released several internal emails from Johnson & Johnson’s Janssen Pharmaceutical subsidiary that raise questions about the company’s disclosure of Risperdal clinical trial data. In one such email from 2003, a researcher expresses concern about “clinical trial data the company has been sitting on since for a long time,” and urges Janssen to “publish not just the clinical efficacy data which should very well be informative and supportive of the use of” Risperdal, but “also the safety data, including events that have been labeled in the past as ‘cerbrovascular adverse events’ and death.”*

According to Bernstein Liebhard, another email from 2004 seems to indicate that Janssen may have been reluctant to disclose unfavorable data from another Risperdal study. “At this point, we must be concerned that this gives the strong appearance that Janssen is purposely witholding (sic) the findings from RIS 232,” the writer warns. “I really do have to speak out and urge that Janssen avoids embarrassment and accusations about suppressing information that is relevant to providers and consumers.**

“A number of Risperdal lawsuits, including many that involve gynecomastia, have been filed in recent years that allege Johnson & Johnson and Janssen concealed Risperdal side effects. Considered in that light, these emails are very interesting,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.

Risperdal Lawsuits
Risperdal is an antipsychotic medication that has been on the market since 1993. Court records indicate that 250 Risperdal lawsuits, including many that allege a connection between Risperdal and gynecomastia, are currently pending in a consolidated litigation underway in the Pennsylvania Court of Common Pleas in Philadelphia. Among other things, plaintiffs in Risperdal gynecomastia lawsuits allege that Johnson & Johnson downplayed Risperdal’s association with male breast growth, and accuse the company of improperly marketing the drug for use in children. (Risperdal Litigation, case number 100300296)

The emails in question where released by the U.S. Department of Justice when it announced earlier this month that Johnson & Johnson and its Janssen unit had agreed to pay $2.2 billion to settle criminal and civil charges regarding the improper marketing of Risperdal and other drugs. Among other things, the companies were accused of misbranding Risperdal and promoting off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities. According to the Justice Department, Risperdal was not approved for any pediatric uses until 2006. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for injury-related damages, including medical bills, lost wages and pain and suffering. To learn more about Risperdal, including the potential side effects of Risperdal in children, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.


About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
2. The Consumer Justice Foundation Launches, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
3. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
4. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
6. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
7. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
8. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
9. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
11. Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor ... application server to improve system efficiency and reliability. , The new Q-Suite 6 platform ... standards, the system avoids locking itself into a specific piece of software for many ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: